EGFR and non-small cell lung carcinoma: Previous clinical trials have demonstrated that EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, dramatically improve the survival of patients with NSCLC harboring EGFR-activating mutations3–5.